Quest Diagnostics Incorporated (DGX)

NYSE · Diagnostics & Research

236.95
+1.43 (+0.61%)
Updated Aug 18, 6:51 PM ET
AI Rating
Buy
Overall Score
70
Trend
75
Momentum
62
Risk
73

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Feb 24, 2026 120 sessions Aug 14, 2026

AI Analysis

Quest Diagnostics Incorporated is trading at $236.95, up 0.61% on the session. The 50 day average sits at $215.36 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 64.2, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $201.00 with resistance near $240.13, so that band frames the current range. Average daily movement is roughly $5.32, or about 2.2% of the share price, which is what any stop placement has to allow for. The overall health score of 70 out of 100 combines a trend score of 75, momentum of 62 and a risk score of 73.

Technical indicators

RSI (14)
64.2
strong
MACD
6.777
bearish crossover
SMA 20
230.61
SMA 50
215.36
SMA 200
--
unknown
ATR (14)
5.32
avg daily range
Support
201.00
Resistance
240.13
Volume vs 20d
0.50x
below average
Volatility
32.1%
annualised
1 month
+11.93%
3 months
+24.72%

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.